Sign In
Buy RGNX
$6.69
+0.170 (+2.61%)
At Close: Jun 03, 2026
FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year
12:01pm, Tuesday, 19'th Aug 2025
The U.S. Food and Drug Administration (FDA) on Monday extended its review timeline for REGENXBIO Inc.'s RGNX Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121) for Mucopolysacc
REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
05:00pm, Monday, 18'th Aug 2025
RGX-121 would be the first and only potential one-time commercially-available therapy designed to directly address the underlying genetic cause of Hunter syndrome, if approved Commercial launch plans
REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript
09:11am, Friday, 08'th Aug 2025
REGENXBIO Inc. (NASDAQ:RGNX ) Q2 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Curran M. Simpson - President, CEO & Director Mitchell Chan - Executive VP & CFO Patrick J.
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
09:21am, Thursday, 07'th Aug 2025
Regenxbio (RGNX) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $1.05 per share a year ago.
REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights
07:05am, Thursday, 07'th Aug 2025
RGX-202 in Duchenne muscular dystrophy on track for topline results 1H 2026 and BLA submission mid-2026 Pivotal trial enrollment accelerated, expected to complete in October 2025 ahead of previous gui
REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
07:00am, Thursday, 07'th Aug 2025
A pivotal Phase IIb/III clinical trial using suprachoroidal delivery for treatment of diabetic retinopathy will be initiated New Phase II ALTITUDE ® trial data demonstrate a durable safety and effica
REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights
07:05am, Thursday, 31'st Jul 2025
ROCKVILLE, Md. , July 31, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 7, at 8:00 a.m.
Construct including CT domain demonstrated higher levels of microdystrophin protein, increased muscle force, and improved resistance to damage in mice lacking dystrophin REGENXBIO's next-generation in
Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome
04:02pm, Friday, 06'th Jun 2025
REGENXBIO specializes in gene therapies using proven AAV technology. RGX-121, targets Hunter syndrome and is under FDA review, with a PDUFA date set for November 9, 2025. We believe the upcoming FDA d
Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer
11:43am, Thursday, 05'th Jun 2025
RegenXBio Inc. RGNX revealed new interim data on Thursday from the Phase 1/2 AFFINITY DUCHENNE trial.
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
07:05am, Thursday, 05'th Jun 2025
RGX-202 demonstrating consistent evidence of positively changing disease trajectory for Duchenne All dose level 2 participants exceeded external natural history controls on all functional measures Bi
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202
07:05am, Monday, 02'nd Jun 2025
Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial ROCKVILLE, Md.
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million
04:05pm, Monday, 19'th May 2025
$150 million secured at closing extends cash runway into early 2027 REGENXBIO retains additional potential non-dilutive funding opportunities, including monetization of Priority Review Voucher (PRV) a
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
07:13am, Wednesday, 14'th May 2025
PARAMUS, N.J. , May 14, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd.
REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript
07:07am, Tuesday, 13'th May 2025
REGENXBIO Inc. (NASDAQ:RGNX ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Curran Simpson - President & CEO Steve Pakola - Chie
